Cabaletta Bio - CABA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.33
  • Forecasted Upside: 157.76%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$13.32
+0 (0.00%)

This chart shows the closing price for CABA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cabaletta Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CABA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CABA

Analyst Price Target is $34.33
▲ +157.76% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Cabaletta Bio in the last 3 months. The average price target is $34.33, with a high forecast of $50.00 and a low forecast of $25.00. The average price target represents a 157.76% upside from the last price of $13.32.

This chart shows the closing price for CABA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Cabaletta Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
4/4/2024CitigroupBoost TargetBuy ➝ Buy$26.00 ➝ $30.00Low
3/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
3/22/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$34.00 ➝ $35.00Low
3/22/2024HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $30.00Low
2/5/2024Jefferies Financial GroupInitiated CoverageBuy$36.00Low
11/29/2023Morgan StanleyLower TargetOverweight ➝ Overweight$28.00 ➝ $25.00Low
11/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00Low
11/29/2023William BlairReiterated RatingOutperform$38.00Low
11/15/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$40.00 ➝ $50.00Low
11/10/2023HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $25.00Low
11/8/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$16.00 ➝ $28.00Low
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$40.00Low
10/19/2023Stifel NicolausInitiated CoverageBuy$31.00Low
10/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.00Low
9/18/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$14.00 ➝ $39.00Low
9/5/2023CitigroupInitiated CoverageBuy$22.00Low
8/14/2023GuggenheimReiterated RatingBuy ➝ Buy$34.00Low
8/11/2023HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $17.00Low
7/18/2023GuggenheimInitiated CoverageBuyLow
4/3/2023HC WainwrightReiterated RatingBuy$15.00Low
3/22/2023Chardan CapitalReiterated RatingBuy$12.00Low
3/17/2023MizuhoReiterated RatingBuy$10.00Low
3/17/2023HC WainwrightBoost TargetBuy$11.00 ➝ $15.00Low
2/17/2023HC WainwrightReiterated RatingBuy$11.00N/A
2/16/2023Evercore ISIBoost Target$14.00 ➝ $18.00Low
1/27/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$3.00 ➝ $16.00Low
1/3/2023Wells Fargo & CompanyBoost TargetOverweight$4.00 ➝ $14.00Low
11/11/2022Chardan CapitalLower TargetBuy$13.00 ➝ $12.00Low
10/20/2022Evercore ISILower Target$5.00Low
9/14/2022Wells Fargo & CompanyLower TargetOverweight$14.00 ➝ $4.00Low
8/30/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $3.00Low
8/22/2022HC WainwrightReiterated RatingBuyLow
8/12/2022Chardan CapitalLower TargetBuy$17.00 ➝ $13.00Low
5/25/2022MizuhoLower TargetBuy$20.00 ➝ $10.00Low
5/16/2022HC WainwrightReiterated RatingBuy$11.00High
3/18/2022MizuhoLower TargetBuy$22.00 ➝ $20.00High
3/18/2022HC WainwrightLower TargetBuy$22.00 ➝ $11.00High
12/15/2021Morgan StanleyLower TargetOverweight$20.00 ➝ $15.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$17.00High
8/8/2021Evercore ISIReiterated RatingBuy$28.00High
6/29/2021MizuhoInitiated CoverageBuy$22.00High
3/17/2021HC WainwrightBoost TargetBuy$20.00 ➝ $22.00High
1/8/2021Chardan CapitalReiterated RatingBuy$21.00High
10/13/2020HC WainwrightInitiated CoverageBuy$20.00High
7/15/2020Morgan StanleyBoost TargetOverweight$19.00 ➝ $20.00Low
11/27/2019Morgan StanleyInitiated CoverageOverweight$19.00High
11/27/2019Evercore ISIInitiated CoverageOutperform$25.00High
11/19/2019Morgan StanleyInitiated CoverageOverweight$19.00 ➝ $19.00High
11/19/2019Evercore ISIInitiated CoverageOutperform$25.00High
11/19/2019CowenInitiated CoverageOutperformHigh
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/27/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/26/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 10 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/24/2024

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Cabaletta Bio logo
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $13.32
Low: $13.30
High: $14.02

50 Day Range

MA: $19.17
Low: $13.32
High: $24.32

52 Week Range

Now: $13.32
Low: $7.69
High: $26.35

Volume

761,527 shs

Average Volume

941,077 shs

Market Capitalization

$642.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Cabaletta Bio?

The following sell-side analysts have issued research reports on Cabaletta Bio in the last twelve months: Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Stifel Nicolaus, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for CABA.

What is the current price target for Cabaletta Bio?

9 Wall Street analysts have set twelve-month price targets for Cabaletta Bio in the last year. Their average twelve-month price target is $34.33, suggesting a possible upside of 157.8%. Cantor Fitzgerald has the highest price target set, predicting CABA will reach $50.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $25.00 for Cabaletta Bio in the next year.
View the latest price targets for CABA.

What is the current consensus analyst rating for Cabaletta Bio?

Cabaletta Bio currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CABA will outperform the market and that investors should add to their positions of Cabaletta Bio.
View the latest ratings for CABA.

What other companies compete with Cabaletta Bio?

Other companies that are similar to Cabaletta Bio include HilleVax, Mesoblast, Novavax, ProKidney and Prime Medicine. Learn More about companies similar to Cabaletta Bio.

How do I contact Cabaletta Bio's investor relations team?

Cabaletta Bio's physical mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The company's listed phone number is 267-759-3100 and its investor relations email address is [email protected]. The official website for Cabaletta Bio is www.cabalettabio.com. Learn More about contacing Cabaletta Bio investor relations.